Skip to main content English


Dietmar Herndler-Brandstetter
Dietmar Herndler-Brandstetter, PhDGroup Leader

Center for Cancer Research, Comprehensive Cancer Center
Position: Research Associate (Postdoc)

ORCID: 0000-0003-0987-0208
T +43 1 40160 - 57577

Further Information


Colorectal Neoplasms; Immune System; Immunotherapy; Tumor Microenvironment

Research interests

  • Humanized mouse models for translational cancer research and immunotherapy
  • Stromal regulation of immune cell development and anti-tumor immunity
  • Long noncoding RNA regulation of adaptive and anti-tumor immunity

Techniques, methods & infrastructure

  • Next-generation humanized mouse models
  • Patient-derived tumor xenografts
  • Cancer immunotherapies
  • Fate reporter and conditional knockout mouse models
  • scRNA-seq
  • 30+ color full spectrum flow cytometry
  • Multiplex immunohistochemistry

Selected publications

  1. Herndler-Brandstetter*, Ishigame* et al. (2018) KLRG1 + Effector CD8 + T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity, 48(4), pp.716-729.e8. Available at:
  2. Ring*, Herndler-Brandstetter*, Weiskopf* et al. (2017) Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. PNAS, 114(49), pp.E10578-E10585. Available at:
  3. Herndler-Brandstetter*, Shan* et al. (2017) Humanized mouse model supports development, function, and tissue residency of human natural killer cells. PNAS, 114(45), pp.E9626-E9634. Available at:
  4. Shan, Flavell and Herndler-Brandstetter (2022) ‘Development of Humanized Mouse Models for Studying Human NK Cells in Health and Disease’, Methods Mol Biol, 2463, pp.53-66. Available at:
  5. Moritsch et al. (2022) ‘Tyk2 is a tumor suppressor in colorectal cancer’, OncoImmunology, 11(1). Available at: